Performance of the REACH, PARIS, BleeMACS, and PRECISE-DAPT scores for predicting 1-year bleeding events in patients undergoing coronary drug-eluting stent implantation

References

• Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39(2):119–177.
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020. doi:10.1093/eurheartj/ehaa624.
   PubMedGoogle Scholar
• Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68(10):1082–1115. doi:10.1016/j.jacc.2016.03.513.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39(3):213–260.
   PubMed Web of Science ®Google Scholar
• Huo Y, Jeong Y-H, Gong Y, Wang D, He B, Chen J, Fu G, Chen Y, Li J, Li Y, et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Science Bulletin 2019;64(2095–9273):166. doi:10.1016/j.scib.2018.12.020.
   Google Scholar
• Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PW, Ohman EM, Brennan DM, D’Agostino RB, Bhatt DL, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 2010;31(10):1257–1265. doi:10.1093/eurheartj/ehq021.
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 2016;67(19):2224–2234. doi:10.1016/j.jacc.2016.02.064.
   PubMed Web of Science ®Google Scholar
• Raposeiras-Roubin S, Faxen J, Iniguez-Romo A, Henriques JPS, D’Ascenzo F, Saucedo J, Szummer K, Jernberg T, James SK, Juanatey JRG, et al. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: the BleeMACS score. Int J Cardiol 2018;254:10–15. doi:10.1016/j.ijcard.2017.10.103.
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389(10073):1025–1034. doi:10.1016/S0140-6736(17)30397-5.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123(23):2736–2747. doi:10.1161/CIRCULATIONAHA.110.009449.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115(17):2344–2351. doi:10.1161/CIRCULATIONAHA.106.685313.
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44(3):837–845. doi:10.2307/2531595.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27(2):157–172;discussion 207–112. doi:10.1002/sim.2929.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30(1):11–21. doi:10.1002/sim.4085.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Branca M, Serruys PW, Benit E, et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother 2020; pvaa106. doi:10.1093/ehjcvp/pvaa106.
   Google Scholar
• Choi KH, Song YB, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Oh JH, Cho DK, Lee JB, et al. Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an analysis from the SMART-DATE randomized trial. Circ Cardiovasc Interv 2020;13(5):e008530.
   PubMedGoogle Scholar
• Abu-Assi E, Raposeiras-Roubin S, Cobas-Paz R, Caneiro-Queija B, Martinez-Reglero C, Rodriguez-Rodriguez JM, Baz A, Iniguez-Romo A. Assessing the performance of the PRECISE-DAPT and PARIS risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients. EuroIntervention 2018;13(16):1914–1922. doi:10.4244/EIJ-D-17-00550.
   PubMedGoogle Scholar
• Bianco M, D’Ascenzo F, Raposeiras Roubin S, Kinnaird T, Peyracchia M, Ariza-Sole A, Cerrato E, Manzano-Fernandez S, Gravinese C, Templin C, et al. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int J Cardiol 2020;301:200–206. doi:10.1016/j.ijcard.2019.11.132.
   PubMed Web of Science ®Google Scholar
• Choi SY, Kim MH, Cho YR, Sung Park J, Min Lee K, Park TH, Yun SC. Performance of PRECISE-DAPT score for predicting bleeding complication during dual antiplatelet therapy. Circ Cardiovasc Interv 2018;11(12):e006837. doi:10.1161/CIRCINTERVENTIONS.118.006837.
   PubMed Web of Science ®Google Scholar
• Song L, Guan C, Yan H, Qiao S, Wu Y, Yuan J, Dou K, Yang Y, Dangas G, Xu B. Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. Catheter Cardiovasc Interv 2018;91(S1):573–581. doi:10.1002/ccd.27468.
   PubMedGoogle Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2009;361(11):1045–1057. doi:10.1056/NEJMoa0904327.
   PubMed Web of Science ®Google Scholar
• Kim HK, Tantry US, Smith SC Jr., Jeong MH, Park SJ, Kim MH, Lim DS, Shin ES, Park DW, Huo Y, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021;121(4):422–432. doi:10.1055/s-0040-1718729.
   PubMedGoogle Scholar
• Gragnano F, Calabrò P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J 2019;40(2):216–217. doi:10.1093/eurheartj/ehy675.
   PubMed Web of Science ®Google Scholar
• Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, Kato T, Ando K, Nakagawa Y, Furukawa Y, et al. Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2019;12(11):e008307. doi:10.1161/CIRCINTERVENTIONS.119.008307.
   PubMedGoogle Scholar
• Corpataux N, Spirito A, Gragnano F, Vaisnora L, Galea R, Svab S, Gargiulo G, Zanchin T, Zanchin C, Siontis GCM, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J 2020;41(38):3743–3749. doi:10.1093/eurheartj/ehaa671.
   PubMed Web of Science ®Google Scholar